Drug Testing and Analysis (accepted, uncorrected)
Introduction
Since the end of 2012, several European Member States have reported the identification of 4,4'-dimethylaminorex (4,4'-DMAR) ( Figure 1A ) via the European Union 'Early Warning System' on New Psychoactive Substances' (EU Early Warning System). [1] In addition, the recent emergence of at least 27 deaths associated with the consumption of 4,4'-DMAR [1, 2] led to the request of the European Commission to carry out a risk assessment in order to assess control measures across EU Member States. [3] 4,4'-DMAR is a ring-substituted analog of 4-methylaminorex (4-MAR or U4Euh), a stimulant drug of abuse that was popular in the 1980s. [4] Like 4-methylaminorex, 4,4'-DMAR contains two chiral centers which yield the potential for four stereoisomers and two racemic mixtures (i.e. cis-and trans-racemates). A recently carried out study involving the characterization of 4,4'-DMAR obtained from online vendors and case samples revealed the presence of cis-4,4'-DMAR. [2, 5] Aminorex (2-amino-5-phenyl-oxazoline) and its analog 4-MAR ( Figure 1A ) were both first synthesized by McNeil Laboratories in the 1960s to evaluate their potential as appetite suppressants. [6, 7] Aminorex was introduced as a prescription drug for weight loss in Europe in 1965 under the trade names Menocil and Apiquel but withdrawn shortly afterwards due to fatal complications related to pulmonary hypertension. [8, 9] While 4,4'-DMAR is currently not a controlled substance, 4-MAR (cis-racemate) is classified as a Schedule I substance under the United Nations Convention on Psychotropic Substances 1971, while aminorex is classified as a Schedule IV substance. [10] Clinical observations related to 4,4'-DMAR intoxication included a range of adverse effects such as agitation, hyperthermia, foaming at the mouth, breathing problems and cardiac arrest. [11] Little information is available regarding the biological mechanism of action for these substances. The related compound aminorex is a substrate for monoamine transporter proteins, which evokes transporter-mediated release of the monoamine neurotransmitters dopamine, norepinephrine, and serotonin (5-HT) in the central nervous system. [12] [13] [14] A previous study revealed that cis-4,4'-DMAR is a powerful monoamine-releasing agent that displays low nanomolar potency at all three monoamine transporters. [5] The work presented in this study describes the synthesis and analytical characterization of 3',4'-methylenedioxy-4-methylaminorex (MDMAR) ( Figure   1A ). Currently, chemical, pharmacological and clinical information on MDMAR appears to be absent in the scientific literature. There is also little evidence to suggest MDMAR is being used as a NPS. However, similar to the work described previously on 4,4'-DMAR, this investigation was also instigated by the donation from an online vendor. Therefore, its appearance on the recreational market could not be fully excluded. Both cis and trans isomeric forms of MDMAR ( Figure   1B ) were synthesized and subjected to analytical characterization using LC-MS, GC-MS, NMR and HR-MS platforms. This was followed by the characterization of the donated vendor MDMAR sample and the identification of the corresponding isomer. Previously published work on the releasing effects of the cis-4,4'-DMAR included the comparison with d-amphetamine, aminorex and cis-4-MAR. [5] In the present study, the monoamine transporter activity of cis-MDMAR, trans-MDMAR, cis-4,4'-DMAR and trans-4,4'-DMAR have been evaluated. In these experiments, the non-selective monoamine releasing agent (+)-3,4-methylenedioxymethamphetamine (MDMA) was included as a standard reference compound with known pharmacology. [15] Experimental
Reagents and standards
All reagents and dry solvents used in the syntheses were obtained from Sigma 
Syntheses
Unless otherwise stated, the synthesis procedures reported here were essentially adapted from the method reported previously by Brandt et al. for the preparation of cis-and trans-4,4'-DMAR isomers ( Figure 1C ). [5] 3',4'-Methylenedioxynorephedrine 
Instrumental analysis

Gas chromatography quadrupole mass spectrometry
Samples were prepared to give a 1 mg/mL solution in methanol and analyzed on The following gradient elution program was used: 0-4 min 2% B, followed by an increase to 30% within 30 min, reaching 80% within 33 min before returning to 2% within 40 min.
Nuclear magnetic resonance spectroscopy
For NMR analysis, the MDMAR standards and the vendor sample were prepared in deuterated dimethyl sulfoxide (DMSO-d6). 1 H (600 MHz) and 13 C NMR spectra were recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 1 H NMR spectra were referenced to an external TMS reference at δ = 0 ppm.
High resolution electrospray mass spectrometry
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap Discovery (Thermo Fisher, UK). Samples were dissolved in acetonitrile/water
(1:1, containing 0.1% formic acid) and infused at a rate of 5 μL/min. Full accurate high-resolution (30000) mass scans were performed in positive electrospray mode. Measured accurate masses were within ± 5ppm of the theoretical masses. The following conditions were used: drying gas (N2) 10 and tube lens 77 V.
X-ray crystallography
Intensity data were collected at 100(2) K using a MiTeGen micromount on a
Bruker APEX Duo CCD diffractometer equipped with an Oxford Cobra cryosystem. Data were collected using ω and φ scans, corrected for Lorentz and polarization effects, and integrated using the Bruker APEX program suite. [16] Structures were solved by direct methods and refined with least squares procedures. [17] All non-hydrogen atoms were refined anisotropically and hydrogen atoms were placed geometrically in the calculated positions using a riding model except for the amino group where hydrogen atoms were located and refined.
Data collected using Cu Kα radiation Program of the National Institute on Drug Abuse (Baltimore, MD, USA). Rats were euthanized by CO2 narcosis and brains were processed to yield synaptosomes as previously described. [18, 19] Time-course evaluation revealed that cis-MDMAR was subject to isomerization in aqueous assay buffer after approximately 40 min. Thus, for this compound, drug dilutions were prepared immediately prior to assay initiation to avoid the potential for isomerization.
Results and discussion
The presence of (±)-cis-4,4'-DMAR on the European market became apparent following a number of notifications to the EU Early Warning System and from reports published in the scientific literature, [1, 2] which triggered an in-depth chemical and analytical characterization and evaluation of its monoamine transporter activity. [5] While cis-4,4'-DMAR has also been advertised under the name 'Serotoni', [20] data about availability, prevalence of use and properties of MDMAR are currently unavailable. However, since this substance was donated from an online vendor it was deemed important to chemically profile this substance as a potential new psychoactive substance as it seemed possible that it might also potentially become available on the drug market. A number of ringsubstituted aminorex analogs have been occasionally discussed, for example on the now defunct Hive forum or in the literature, [21] and it appeared that some discussion has also occurred on MDMAR ('MDMAminorex') on an online forum. [22] So far, however, it is unclear whether MDMAR is available for purchase from online retailers.
Synthesis
The synthesis employed for the preparation of the racemic isomers of MDMAR was based on the synthetic pathways outlined in the literature. [5, 6, 23, 24] The thionyl chloride, which spontaneously cyclized [25] to form the desired trans-MDMAR isomer.
X-Ray Crystallography
The structure of the synthesized cis-MDMAR isomer is shown in Figure 1D . After repeated crystallization from propanol, a single colorless very thin plate crystal was used for analysis. The structure in the triclinic space group Pī, confirms the 4S,5R-cis arrangement of the oxazoline moiety. Bond lengths and angles in the oxazoline moiety are similar to those found in (4S,5R)-(-)-cis-4-methyl-5-phenyloxazoline-2-amine. [25] The angle of the oxazoline plane to benzodioxole 
Gas chromatography mass spectrometry
The chromatographic method used was able to achieve separation between the two isomers obtaining a retention time of 7.97 minutes for the cis isomer ( Figure   2A ) and a retention time of 7.88 minutes for the trans isomer ( Figure 2B ). The EI mass spectra obtained for the synthesized cis and trans racemates were similar as expected. The base peak was observed at m/z 70 and indicated the loss of 3,4-methylenedioxybenzaldehyde, which gave rise to a radical cation. The suggested species, with molecular formula C3H6N2, which may be the 3-methylaziridin-2-imine fragment, was consistent with the EI-MS data reported for 4-MAR [26] and 4,4'-DMAR. [5] The loss of a methyl group (m/z 205) from the molecular ion was observed while the presence of an acylium ion was represented by the ion at m/z 149, followed by a loss of CO to give m/z 121. The observed species at m/z 176 was due to the presence of an aziridinium ion. Overall, it was found that the main principles of fragmentation were in agreement with the EI spectra reported previously on 4,4'-DMAR. [5] The proposed electron ionization fragmentation pattern for 3',4'-methylenedioxy-4-methylaminorex by GC-MS is outlined in Figure 2C . Figure 3A) . The loss of 43 Da (HNCO) was described previously in studies involving mass spectrometric analysis of 4,4'-DMAR [5] and 4-MAR. [27] However, 
Nuclear magnetic resonance spectrometry
The NMR spectra associated with both racemic MDMAR isomers shared some key characteristics, which were consistent with those reported previously for cis and trans 4,4'-DMAR and 4-MAR. [5] However, there were also differences in Monoamine transporter activity Figure 5 shows the dose-response effects of cis-DMAR, trans-DMAR, cis-MDMAR and trans-MDMAR on transmitter release at DAT, NET and SERT. Table 1 summarizes potency values as concentrations producing 50% of maximal release (EC50 concentration) for the test drugs based on data depicted in Figure   5 . All of the ring-substituted 4-methylaminorex analogs displayed potent substrate-type releasing activity at DAT, with EC50 values ranging from 10.2 ± 1.2 nM for cis-MDMAR to 36.2 ± 3.6 nM for trans-MDMAR. The drugs were also potent releasers at NET, with EC50 values ranging from 11.8 ± 2.0 nM for cis-DMAR to 38.9 ± 4.7 nM for trans-MDMAR. All of the 4-methylaminorex analogs were more potent than MDMA as substrates at DAT and NET (see Table 1 ).
Activity at SERT varied from 17.7 ± 2.3 nM for cis-DMAR to 73.4 ± 12.0 nM for trans-MDMAR. The test drugs were fully efficacious in their ability to evoke release at DAT, NET and SERT (i.e., drug effects achieved 100% of maximal release), with the exception of trans-DMAR, which functioned as a "partial" releaser at SERT (75% maximal release). Subsequent experiments revealed that trans-DMAR is fully efficacious as an uptake blocker at SERT (data not shown), suggesting this drug displays "hybrid" activity across monoamine transporters.
It is proposed that trans-DMAR acts as a substrate-type releaser at DAT and NET, but an uptake blocker at SERT. When considering the transporter selectivity of the test compounds, all were essentially non-selective, with DAT/SERT ratios ranging from 0.6 for MDMA to 4.3 for cis-DMAR.
(Insert Figure 5 and Table 1 
Confirmation of cis-MDMAR in vendor sample
The sample donated from an online vendor and thought to contain MDMAR was subjected to identical analytical conditions. GC-MS studies showed that the online vendor product consisted predominantly of the cis MDMAR isomer (90%).
The retention time (7.97 minutes) and fragmentation pattern of the vendor sample was congruent with that of the cis MDMAR standard. LC-MS studies, which included the comparison with the synthesized cis standard, also confirmed the presence of cis MDMAR in the vendor sample. Inspection of the LC chromatogram derived from the donated sample also suggested that the product contained a significant amount of the trans isomer. However, based on the observations described and investigated above, it was determined that this detection of the trans isomer was formed artificially following exposure to the water-containing mobile phase. Analysis by GC-MS, on the other hand, did not result in isomerization and detected the trans species at a much less significant level (10%). The 1 H and 13 C NMR spectra were in agreement with the GC and LC data confirming the presence of cis MDMAR in the vendor product.
Conclusion
The preparation and analytical characterization of cis-and trans-3',4'-methylenedioxy-4-methylaminorex (MDMAR) demonstrated facile differentiation between both isomers but also showed a potential for misinterpretation under HPLC conditions when it was observed that the aqueous mobile phase caused isomerization of the cis-to the trans form. The high potency of ring-substituted methylaminorex analogs and their ability to be fully efficacious substrate-type releasers might contribute to the possibility of a range of serious side effects after high dose exposure and/or when combined with other substances that act on similar targets. Psychotic symptoms, agitation and hyperthermia could result from overstimulation of central dopamine and 5-HT systems, whereas dangerous cardiovascular effects could be produced by excessive norepinephrine release in the periphery. [28, 29] The comparison between the monoamine transporter activity of cis-and trans-4,4'-dimethylaminorex pointed towards the possibility that the trans-species might display "hybrid" activity across monoamine transporters. This is the first report on the characterization of MDMAR, which demonstrates the continuous need to remain vigilant on the availability of newly emerging psychoactive substances. [30] Figure 5 .
